



REVIEW ARTICLE

# An Insight into the cardioprotective properties of *Prisniparni* (*Desmodium gangeticum* (L)DC) through its secondary metabolites.

Mridula. M.K<sup>1</sup>, P.Y. Ansary<sup>2</sup>, Sara Monsy Oommen<sup>3</sup>.

<sup>1</sup>PhD Scholar, Dept. of Dravyaguna vijnana, Govt. Ayurveda College, Tripunithura.

<sup>2</sup>Professor&HOD, Dept. of Dravyaguna vijnana, Govt. Ayurveda College, Tripunithura.

<sup>3</sup>Professor&HOD, Dept. of Dravyaguna vijnana, Govt. Ayurveda College, Kannur.

\*Email: [drmidulamk@yahoo.com](mailto:drmidulamk@yahoo.com)

## ARTICLE HISTORY

Received: 02 June 2023

Accepted: 22 June 2023

Available online

Version 1.0 : 30 June 2023

## Keywords

*Desmodium gangeticum*, secondary metabolites, pterocarpan, cardio protection.

## Additional information

**Peer review:** Publisher thanks Sectional Editor and the other anonymous reviewers for their contribution to the peer review of this work.

**Reprints & permissions information** is available at <https://keralajournalofayurveda.org/index.php/kja/open-access-policy>

**Publisher's Note:** All Kerala Govt. Ayurveda College Teacher's Association remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Copyright:** © The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited (<https://creativecommons.org/licenses/by/4.0/>)

## CITE THIS ARTICLE



Mridula M K, Ansary P Y, Oommen S M. An Insight into the cardioprotective properties of *Prisniparni* (*Desmodium gangeticum* (L)DC) through its secondary metabolites. Kerala Journal of Ayurveda. 2023;

2(2): 30-37. <https://doi.org/10.55718/kja.164>

## Abstract

*Prisniparni* is a medicinal plant that is often used in the formulation of many Ayurvedic medicines. Even though some controversy exists about the botanical source of the plant, Kerala physicians generally use *Desmodium gangeticum* (Linn.) DC. of the Leguminosae family as *Prisniparni*. Specific usage of the drug in *hridroga* is emphasized in traditional Ayurvedic textbooks and regional books of Kerala. The results of recent preclinical studies support *Prisniparni*'s traditional use in *hridroga*. However, their clinical and scientific validation is lacking, especially in terms of their mechanism of action. The therapeutic potential of medicinal plants depends on their secondary metabolites. The plant's pharmacological activity may be due to the combined activity of its secondary metabolites. Based on this, a literature search on secondary metabolites of *Desmodium gangeticum* (Linn.) DC was done by electronic and hand search. Results of this review revealed the richness of alkaloids and polyphenols in *Desmodium gangeticum* (Linn.) DC which are antioxidant and anti-inflammatory in nature. The findings support the plant's cardioprotective potential and its traditional use since inflammation and oxidative stress are reported to be major contributors to cardiovascular diseases.

## Introduction

*Prisniparni* is a plant with various uses in Ayurveda dating back to the Vedic period. It's listed as a part of *dasamoola*<sup>1</sup> and a member of the *amsumatidwaya*<sup>2</sup> in the Samhita period. Roots are the most useful part of the plant<sup>3</sup>, but seeds and leaves are also useful<sup>4</sup>. It is used by Ayurvedic physicians in vitiated conditions of *vata*, *Jwara* (fever)<sup>5</sup>, *kasa* (cough), *swasa* (Bronchitis and asthma)<sup>6</sup>, *hridroga* (cardiopathy)<sup>7,8</sup> etc. But some controversy exists regarding the botanical identity of the drug *Prisniparni* in southern and northern part of India. It is described that the controversy arises due to regional variation. However, the Physicians of Kerala generally uses the plant *Desmodium gangeticum* (Linn.) DC. of Leguminosae family as *Prisniparni*. It is commonly known as *orila* in Malayalam<sup>9</sup>.

Specific usage of the plant in the management of *Hridroga*<sup>10</sup> is emphasized in *Ayurveda classical text books and some regional Ayurveda books of Kerala*. Acharya Charaka has listed it under *ghrita* preparations

advocated orally in curing *hridroga* and *Paithikahridroga* in *trimarmeeeya chikitsa adhyaya*<sup>11</sup>. He referred it as the best of the *sangrahika* (astringent), *vatahara* (alleviates vata), *deepaneeya* (promotes digestion), and *vrishya* (increases virility) medications<sup>12</sup>. It has been identified by Acharya Susruta as a component of the *rodradhi basthi*, a panchakarma therapy formulation used to treat *hridroga*<sup>13</sup>. Acharya Vagbhata mentioned *Prisniparni* under *Vidaryadi gana* having *hridaya karma* in *Ashtanga Hridaya*<sup>14</sup>. The drug serves as an ingredient of medicated ghee, *Amritaprasha ghrita*, which is *hridayamayapaham*<sup>15</sup>. *Prisniparni* is included in the preparation of *Mahasneha* (mixture of all the four fats, ghee, oil, muscle fat and marrow) which is administered orally for curing *vatika hridroga*<sup>16</sup>. *Ksheerapaka* made up of *prisniparni* root is recommended for oral administration in *hridayagata vata*, according to *vatavyadhi chikitsa*.<sup>17,18</sup> It is evident from all of these formulations that *Prisniparni* plays a crucial role in *hridroga chikitsa*. Therefore, an in-depth understanding of the plant's pharmacological, biochemical, and biomolecular properties will improve its rational application in the avoidance and control of *hridroga*. Recent preclinical investigations significantly indicate the efficacy of *Desmodium gangeticum* (L) DC in cardiac hypertrophy,<sup>19,20</sup> myocardial reperfusion injury<sup>21,22,23</sup> and myocardial infarction<sup>24</sup>. In a clinical study, *ksheerapaka* made up of *prisniparni* root was found to reduce symptoms of stable angina in patients<sup>25</sup>. In vitro experimental studies *ksheerapaka* of *Prisniparni* revealed its cardiogenic<sup>26,27</sup> and antioxidant properties<sup>28</sup>. These findings support the traditional use of *Prisniparni* in *Hridroga*.

Plants have been used as a source of biologically active compounds for centuries. Increasingly, people are turning to plant-herbal remedies to avoid synthetic drugs' long-term side effects. Researchers are still investigating medicinal plants for potential drug applications. *Prisniparni* is one of several plant drugs available for the treatment of

heart disease. They can be used alone or in combination with chemical drugs to prevent cardiovascular problems<sup>29</sup>. However, their clinical and scientific validation is lacking, especially in terms of their mechanism of action<sup>30</sup>. The secondary metabolites of medicinal plants determine their therapeutic potential. Most secondary metabolites have pharmacological, toxicological, or biological consequences. There is scientific evidence that mixing various defensive compounds results in a synergistic potentiation of biological activities. As a result, the plant's pharmacological effects may be due to the combined action of its secondary metabolites<sup>31</sup>. Evaluation *Desmodium gangeticum* (L) DC of revealed the richness of alkaloids and polyphenols, which may be reason of its high therapeutic potential. Considering all these factors, this review is an attempt to explain the cardioprotective activity of the plant DG based on its reported secondary metabolites. Thereby providing a possible explanation on the use of *Prisniparni* in the management of heart disease.

## Materials and Methods

All available information on secondary metabolites of *Desmodium gangeticum* (L) DC was gathered through an electronic search and a library search of peer-reviewed academic articles. Hand search of Ayurveda classical text books, unpublished PG thesis and other relevant text books were also conducted.

## Results

*Desmodium gangeticum* (L) DC is reported to be rich in alkaloids, flavonoids, terpenoids, and steroids. The abundance of alkaloid and phenolic groups in *Desmodium* species may explain their diverse biological functions, including *Desmodium gangeticum* (L) DC.<sup>32</sup> The table below lists the key classes of phytoconstituents of the plant, which include alkaloids, flavonoids, steroids, and terpenoids.<sup>33,34,35</sup>

Table: 1 - Alkaloids

Sl no	Aerial part	Root
1	Indole-3-alkylamines	Berberine
2	N, N-dimethyl tryptamine	Pilocarpine
3	5-methoxymethyl tryptamine	Kopsinine
4	5-methoxy amine oxide	Galanthamine
5	Hordenine	Atropine
6	Candicine	Carboline
7	β-phenylethylamine,	Gangenoid
8	Hypaphorine	N,Ndimethyltryptamine,
9	N-methyl tyramine	N,Ndimethyltryptamine N <sub>b</sub> -oxide
10		Hypaphorine
11		Hordenine
12		Candicine
13		N-methyltyramine,
14		Beta phenylethylamine.
15		Halostachine

Table 2 - Polyphenols

	Aerial part	Root	Leaves
Pterocarpan	-	Gangetial Gangetin Desmocarpine Desmodin Gangetinine	-
Flavones	-	4-O-alpha-L rhamnopyranosyl (1-6)-beta-d glucopyranoside	-
Phenolic acid	1.salicylic acid 2.caffeic acid 3. chlorogenic acid 4. Protocatechuic acid (3,4-dihydro benzoic acid) 5. gallic acid	-	-
Flavonoid glycoside	Rutin Quercetin-7-O-beta-D glycopyranoside, kaempferol-7-O-beta-D glycopyranoside 4,5,7 trihydroxy 8-prenyl favone 4-O-L-rhamnopyranosyl (1-6) D glycopyranoside 8-C-prenyl-5,7,5, trimethoxy-3,4- methylene dioxy flavones	-	-
Isoflavone			Genistein 2'-hydroxygenistein
Isoflavanone			Dalbergioidin Diphysolone kievitone. desmocarpin

Table 3: Terpenoid and steroids

	Aerial part	Seed
Terpenoid	beta-Amyrone Stigmasterol	
Steroids	lupeol beta-sitosterol	Amino glucosylglycero-lipid

Gino A Kurian et.al<sup>36,37</sup> used GC-MS to identify 4-[2-(dimethyl amino) ethyl] phenol, a G protein agonist and alpha-asarone, a potent antioxidant and 2,5-bis (1,1-dimethyl ethyl) phenol

from the root of the plant DG. These constituents are well-known for their effects on cardiac tissues.

**Table 4:** Secondary metabolite and biological activity.

Secondary metabolite	Biological activity
Salicylic acid.	Blocks HMGB1, a protein that causes inflammation in injured tissues.
Caffeic Acid	Antioxidant and anti-inflammatory properties. Prevents oxidative stress and thus DNA damage caused by free radicals.
Chlorogenic acid	anti-oxidant, scavenges free radicals, which inhibits DNA damage. Anti-inflammatory, antilipidemic, and antioxidant. Protects vascular health by inhibiting ED.
Protocatechuic acid (3,4-dihydro benzoic acid)	Anti-inflammatory Anti-oxidant promotes the expression of antioxidant enzymes by activating Nrf2 signalling pathways, which reduces oxidative stress and its accompanying issues like endothelial dysfunction.
Gallic acid	Antioxidant anti-inflammatory Improves cardiac dysfunction, reduces cardiac fibrosis
Rutin	Anti-inflammatory and antioxidant activity. Through ROS-scavenging processes, they lower the degree of oxidative stress. alleviated cardiac dysfunction and decreased cardiomyocyte apoptosis in septic mice ERK, JNK, and MAPK pathway are suppressed to prevent heart hypertrophy. protects the heart by activating SIRT1/NRF2 pathway. By lowering growth factor and MMP expressions, rutin reduces heart fibrosis. Reduces pathological cardiac remodelling.
Quercetin	antioxidant. studies have reported that quercetin may be applied to cardiovascular diseases, including atherosclerosis, ischemia-reperfusion injury, cardiotoxicity, and hypertension.
Pterocarpan	Could be protein tyrosine phosphate kinase inhibitors Which can significantly contribute to cardiovascular disease and endothelial dysfunction.
Gangetin	In the exudative and proliferative stages of inflammation, showed significant anti-inflammatory effect. In the hot plate method and acetic acid-induced writhing, analgesic effect was observed in a dose-dependent manner.
Desmodin	a potential inhibitor of cyclin-dependent kinase 5. Cyclin-dependent kinase inhibitor drugs have emerged as potential anti-inflammatory agents that can influence the resolution of inflammation.
kaempferol-7-O-β-D glycopyranoside	free radical scavenger
Gangenoid	Anti-inflammatory
(17Z,20Z)-hexacosyl-17,20-dien-9-one (HCDO)	Anti-inflammatory
Berberine	Recent researches reported biological activities including the reduction of blood sugar, regulation of lipids, as well as anti-arrhythmic and cardio-protective effects
Asarone	Anti-inflammatory
Hordenine	Positive inotropic effect upon the heart, increases systolic and diastolic blood pressure, peripheral blood flow volume
Atropine	provides potential clinical use in the targeted therapy of an abnormally low heartbeat since it increases cardiac rate and the force of cardiac contraction.
Berberine	Due to its effects on potassium channels prevents ventricular fibrillation. Antiplatelet activity, lipid lowering activity, antiarrhythmic effect
Pilocarpine	maybe by activating K <sup>+</sup> current mediated by M3 receptors, helps to change the cellular electrical properties of the hearts.
Galanthamine	Alleviate inflammation, In myocardial I/R rats, activating the AMPK/Nrf2 pathway reduced ERS-associated apoptosis, myocardial fibrosis, and cardiac dysfunction.
Carboline	Antioxidant, Cardioprotective

## Discussion

Cardiovascular disease is caused by several factors, such as reactive oxygen species formation, oxidative stress, immune cells, and inflammatory signalling. And among the multiple pathologies, atheroma formation leading to atherosclerosis is considered as the beginning of CVDs. So, the drugs having lipid lowering, antiplatelet, thrombolytic, antioxidant, anti-inflammatory and free radical scavenging activities will be beneficial in the management.

Oxidative stress has a significant impact on the pathophysiology and development of cardiovascular disease. And one of the main causes of oxidative stress is the production of reactive oxygen species (ROS). In addition, both are associated with endothelial damage linked to cardiovascular disease, atherosclerosis progression, and myocardium injuries caused by sustained myocardial infarction and ischemia reperfusion. It is well known that a lack of nitric oxide (NO)-dependent vasorelaxation poses a serious threat to the development of cardiovascular disease, and ROS degradation is one factor contributing to the reduction in NO bioavailability. Therefore, antioxidants are becoming increasingly popular strategies for reducing ROS in the vasculature. Polyphenols are plant metabolites that have antioxidant properties and regulate various cellular antioxidant defence mechanisms. They change a wide range of targets involved in the pathogenesis of cardiovascular disease, such as eNOS and NO, inflammatory cytokines including TNF, IL-6 and IL-8, VCAM-1 and ICAM-1, as well as SIRT1, MAP38 kinase, NF-B, and AP-1, among many others<sup>70</sup>.

A diet high in flavonoids may lower the chance of developing cardiovascular disease, according to epidemiological studies. Quercetin in particular helps to alleviate endothelial dysfunction and lower blood pressure. This may be accomplished by enhancing the strong vasodilator NO's bioavailability<sup>71</sup>. *Desmodium gangeticum* (L) DC is rich in polyphenols and that may be the reason behind its antioxidant capacity and cardio protection. Recently, there is growing consensus on the hypothesis that the specific intake of food and drinks with high concentrations of flavonoids may reduce CVD risk<sup>72</sup>. In *Ashtanga hridaya Uttara sthana*, it is advised to give cow's milk or goat's milk medicated with roots of *Sthira (Prisniparni)* for children who were not receiving enough breast milk from mother. This points out its nutritional value as well<sup>73</sup>.

The second-largest class of natural isoflavonoids is called pterocarpans<sup>74</sup> which is most frequently found in the Fabaceae family<sup>75</sup>. Pterocarpans can lower total and low-density lipoprotein cholesterol levels, which lowers the chance of developing a number of ailments, according to

scientific research<sup>76</sup>. They also have platelet aggregation inhibition activity, anti-oxidant activity and can modulate inflammation<sup>77,78</sup>. *Desmodium gangeticum* (L) DC is a rich source of pterocarpan like Gangetin, Gangetin, Desmocarpane, Desmodin, and Gangetinine. A recent in silico molecular docking investigation suggested that *Desmodium gangeticum* (L) DC pterocarpan might act as PTP kinase inhibitors. This enzyme significantly contributes to cardiovascular disorders<sup>79</sup>. Researches also reported the promising activities of alkaloids of *Desmodium gangeticum* (L) DC especially anti-inflammatory and anti-oxidant activity that supports cardio protection.

When it comes to endothelial cell activation and dysfunction, which are linked to CVDs, the inflammatory response is quite important<sup>80</sup>. Various inflammatory cells have been shown to contribute to vascular oxidative stress, according to recent studies. Researchers demonstrated the protective effect of classical therapies for inflammatory disorders in CVDs, which have a feature of normalization of oxidative stress<sup>81</sup>. *Desmodium gangeticum* (L) DC contains many phytochemicals with anti-oxidant and anti-inflammatory activity and this may make it a potent drug candidate for the management of cardiovascular diseases.

## Conclusion

This review reveals the pharmacological activity of several secondary metabolites of *Desmodium gangeticum*(L)DC, contributing insight into its cardioprotective potential and substantiating its traditional use. Through the study of secondary metabolites in medicinal plants, we can better explain how drugs work to the scientific community. Furthermore, it is necessary to conduct computational system biology studies on Ayurvedic medicinal plants using their secondary metabolites. This will help to understand the action of drugs in various disease pathways and help drug discovery process.

## References

1. Susruta.Illustrated Susruta Samhita Vol I. Trans Prof. KR Srikantha Murthy. Reprint ed. Varanasi: Chaukhambha orientalia;2012. Sutrasthana, Chapter 38. Dravya sangrahaneeya adyaya, Sloka 71; p.274.
2. Vagbhata. Ashtanga Hridayam Vol I. Trans Prof. K R Srikantha Murthy.9th ed.Varanasi: ChaukhambhaKrishnadas Academy; 2012.Sutra sthana,Chapter6.Annasvarupavijnaneeya adhyaya, Sloka 167-168;p.107.
3. Orient Logman.Indian Medicinal Plants. A Compendium of 500 species. Arya Vaidya Sala, Kottakkal; Volume 2. p.319
4. Avasthi, B.K. and Tewari, J.D. (1955), A preliminary phytochemical investigation of *Desmodium gangeticum* DC, I. J. Pharm. Sci., 44: 625 -627. <https://doi.org/10.1002/jps.3030441015>
5. Pandit Narahari. RajaNighantu. Tripathi Indradeva(ed.). Varanasi: Chaukambha Krishnadas Academy;2009.p.68.



6. Bhavamisra. Bhavaprakasha Nighantu. Dr K C Chunekar, G S Pandey (ed.). Varanasi: Chaukambha Bharati Academy; Reprint 2010.p.274-275.
7. Agnivesa.Charaka Samhita Vol V. Trans R K Sharma, Bhagwan Dash.Reprint ed. Varanasi: Chaukambha Sanskrit series office; 2011.Chikitsasthana, Chapter 28. Vatavayadhi chikitsa, sloka 96; p.49.
8. Vagbhata. Ashtanga Hridayam Vol II. Trans Prof. K R Srikantha Murthy.9th ed.Varanasi: Chaukhambha Krishnadas Academy; 2012.Chikitsasthana,Chapter 21. Vatavayadhi chikitsa, Sloka 17; p.500.
9. Orient Logman. Indian Medicinal Plants. A Compendium of 500 species. Arya Vaidya Sala, Kottakkal; Volume 2. p.322.
10. Agnivesa.Charaka Samhita Vol IV. Trans R K Sharma, Bhagwan Dash.Reprint ed. Varanasi: Chaukambha Sanskrit series office; 2011.Chikitsasthana, Chapter 26. Trimarmeeeya chikitsa, sloka 73-75; p.490.
11. Agnivesa.Charaka Samhita Vol IV. Trans R K Sharma, Bhagwan Dash.Reprint ed. Varanasi: Chaukambha Sanskrit series office;2011. Chikitsasthana, Chapter 26. Trimarmeeeya chikitsa, sloka 90-95; p.495.
12. Agnivesa.Charaka Samhita Vol I. Trans R K Sharma, Bhagwan Dash.Reprint ed. Varanasi: Chaukambha Sanskrit series office; 2011.Sutrasthana, Chapter 25. Yajjapurushheeyam Adhyayam, sloka 40; p.427.
13. Susrutha. Illustrated Susruta Samhita Vol II. Trans Prof. KR Srikantha Murthy. Reprint ed. Varanasi: Chaukhambha orientalia; 2012. Chikitsasthana. Chapter 38 Niruhakrama chikitsitam; Sloka 55-59; p.373.
14. Vagbhata. Ashtanga Hridayam Vol I. Trans T. Sreekumar.5th ed. Thrissur: Publication departmentHarisreehospital;2007. Sutrasthana, Chapter15. Shodhanadigana sangrahaneeeyam Adhyayam, Sloka 9-10; p.324.
15. Agnivesa.Charaka Samhita Vol III. Trans R K Sharma, Bhagwan Dash.Reprint ed. Varanasi: Chaukambha Sanskrit series office;2013. Chikitsasthana, Chapter 11. Shophachikitsa, Sloka 35-43; p.467.
16. Vagbhata. Ashtanga Hridayam Vol II. Trans Prof. K R Srikantha Murthy.9th ed. Varanasi: Chaukhambha Krishnadas Academy; 2012. Chikitsasthana, Chapter 6. Chardi hridroga trishna chikitsa, Sloka 39-40; p.277.
17. Agnivesa.Charaka Samhita Vol V. Trans R K Sharma, Bhagwan Dash.Reprint ed. Varanasi: Chaukambha Sanskrit series office; 2011.Chikitsasthana, Chapter 28. Vatavayadhi chikitsa, sloka 96; p.49.
18. Vagbhata. Ashtanga Hridayam Vol II. Trans Prof. K R Srikantha Murthy.9th ed. Varanasi: Chaukhambha Krishnadas Academy; 2012.Chikitsasthana, Chapter 21. Vatavayadhi chikitsa, Sloka 17; p.500.
19. Hitler D, Narayanasamy M, Arumugam P, Vellaichamy E. Desmodium gangeticum root extract attenuates isoproterenol -induced cardiac hypertrophic growth in rats. Journal of Pharmacy & Pharmacognosy Research. 2014;2(5):129-37.
20. Sankar V, Pangayarselvi B, Prathapan A, Raghu KG. Desmodium gangeticum (Linn.) DC. exhibits antihypertrophic effect in isoproterenol-induced cardiomyoblasts via amelioration of oxidative stress and mitochondrial alterations. J Cardiovasc Pharmacol. 2013 Jan;61(1):23-34. doi: 10.1097/FJC.0b013e3182756ad3. PMID: 23052030.
21. Kurian GA, Shabi MM, Paddikkala J. Cardiotoxic and anti ischemic reperfusion injury effect of Desmodium gangeticum root methanol extract. Turk J Biochem. 2010;35(2):83-90.
22. Kurian GA, Paddikkala J. Administration of aqueous extract of Desmodium gangeticum (L) root protects rat heart against ischemic reperfusion injury induced oxidative stress. Indian J Exp Biol. 2009 Feb;47(2):129-35. PMID: 19374168.
23. Kurian GA, Suryanarayanan S, Raman A, Padikkala J. Antioxidant effects of ethyl acetate extract of Desmodium gangeticum root on myocardial ischemia reperfusion injury in rat hearts. Chin Med. 2010 Jan 22; 5:3. doi: 10.1186/1749-8546-5-3. PMID: 20180993; PMCID: PMC2831010.
24. Kurian GA, Philip S, Varghese T. Effect of aqueous extract of the Desmodium gangeticum DC root in the severity of myocardial infarction. J Ethnopharmacol. 2005 Mar 21;97(3):457-61. doi: 10.1016/j.jep.2004.11.028. PMID: 15740881.
25. Anu.T. S. Clinical study to assess the efficacy of sthirasidhapayas in stable angina.PG [Dissertation]. Thrissur. Kerala.Kerala University of Health Sciences. 2018.
26. Sreena Sreekumar.The cardiotoxic (hridya) effect of ksirapakas of sthira dwayam. [Roots of Desmodium gangeticum (Linn). DC. and Pseudarthria viscida (Linn) wight &Arn.PG [Dissertation]. Trivandrum. Kerala. Kerala University of Health Sciences. 2011.
27. Indu.S. In vitro cardiotoxic activity of selected ksheerapakas and their value-added formulations.PG [Dissertation]. Trivandrum.Kerala. Kerala University of Health Sciences. 2015
28. Aswathy Krishna. R. Antioxidant activity of Ksheerapaka of root of Prishniparni-Desmodium gangeticum (Linn.) DC. in oxidative stress induced cardiomyoblasts- An exploratory in vitro study.PG [Dissertation]. Thripunithura. Kerala.Kerala University of Health Sciences. 2022
29. Roodabeh Bahramsoltani, Mohammad Hosein Farzaei, Roja Rahimi ; Herbal Remedies for Atherosclerosis: From Back to the Future, Herbal Medicine: Back to the Future Cardiovascular Diseases (2017) 1: 188. <https://doi.org/10.2174/9781681084893117010007>
30. Meriga B, Ganjaji MS, Parim BN. Phytocompounds as potential agents to treat obesity-cardiovascular ailments. Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Cardiovascular & Hematological Agents). 2017 Aug 1;15(2):104-20.
31. Wink M. Evolution of secondary metabolites in legumes (Fabaceae) S. Afr. J. Bot. 2013;89:164-75.
32. Joshi, B.R., Hakim, M.M. & Patel, I.C. The biological active compounds and biological activities of Desmodium species from Indian region: a review. Beni-Suef Univ J Basic Appl Sci 12, 1 (2023). <https://doi.org/10.1186/s43088-022-00339-4>
33. Ghosal, S., & Banerjee, P.K. (1969). Alkaloids of the roots of Desmodium gangeticum. Aust J Chem. 22, 2029–2031.
34. Vasani D, Vyas H, Panara K, Patel B, Singh P, Vasava A, Patil S. Ethnomedical uses, Phytochemistry, Pharmacological and therapeutic properties of Desmodium gangeticum (L.) DC.: A Scoping Review. Plant Sci. Today [Internet]. 2022 Oct. 1 [cited 2023 Jun. 20];9(4):881-90.
35. Joshi, B.R., Hakim, M.M. & Patel, I.C. The biological active compounds and biological activities of Desmodium species from Indian region: a review. Beni-Suef Univ J Basic Appl Sci 12, 1 (2023). <https://doi.org/10.1186/s43088-022-00339-4>
36. Kurian GA, Paddikkala J. Methanol extract of Desmodium gangeticum DC root mimetic post-conditioning effect in

- isolated perfused rat heart by stimulating muscarinic receptors. *Asian Pac J Trop Med.* 2012 Jun;5(6):448-54. doi: 10.1016/S1995-7645(12)60076-5. PMID: 22575976.
37. Kurian, G.A., Yagnesh, N., SanchitKishan, R. Jose Paddikkala. Methanol extract of *Desmodium gangeticum* roots preserves mitochondrial respiratory enzymes, protecting rat heart against oxidative stress induced by reperfusion injury. *J. Pharm. Pharmacol.* 2008 April;60(4):523-30. doi: 10.1211/jpp.60.4.0016, PMID: 18380926 DOI: 10.1211/jpp.60.4.0016.
  38. Daniel F Klessig et al. Aspirin's Active Metabolite Salicylic Acid Targets High Mobility Group Box 1 to Modulate Inflammatory Responses. *Molecular Medicine*, October 2015
  39. Caffeic Acid is an orally bioavailable, hydroxycinnamic acid derivative and polyphenol, with potential anti-oxidant, anti-inflammatory, and antineoplastic activities. Upon administration, caffeic acid acts as an antioxidant and prevents oxidative stress, thereby preventing DNA damage induced by free radicals
  40. National Center for Biotechnology Information. "PubChem Compound Summary for CID 1794427, Chlorogenic Acid" PubChem, <https://pubchem.ncbi.nlm.nih.gov/compound/Chlorogenic-Acid>. Accessed 17 March, 2023.
  41. Lukitasari M, Saifur Rohman M, Nugroho DA et al. Cardiovascular protection effect of chlorogenic acid: focus on the molecular mechanism [version 1; peer review: 1 approved, 2 approved with reservations]. *F1000Research* 2020, 9:1462 (<https://doi.org/10.12688/f1000research.26236.1>).
  42. Masella R, Santangelo C, D'Archivio M, Li Volti G, Giovannini C, Galvano F: Protocatechuic acid and human disease prevention: biological activities and molecular mechanisms. *Curr Med Chem* 2012, 19:2901–2917
  43. Masella R, Vari R, D'Archivio M, Di Benedetto R, Matarrese P, Malorni W, Scaccocchio B, Giovannini C: Extra virgin olive oil biophenols inhibit cell-mediated oxidation of LDL by increasing the mRNA transcription of glutathione-related enzymes. *J Nutr* 2004, 134:785–791
  44. Juurlink BH, Azouz HJ, Aldalati AM, Altinawi BM, Ganguly P. Hydroxybenzoic acid isomers and the cardiovascular system. *Nutr J.* 2014 Jun 19;13:63. doi: 10.1186/1475-2891-13-63. PMID: 24943896; PMCID: PMC4074389.
  45. Bai J, Lin QY, An X, Liu S, Wang Y, Xie Y, Liao J. Low-Dose Gallic Acid Administration Does Not Improve Diet-Induced Metabolic Disorders and Atherosclerosis in Apoe Knockout Mice. *Journal of Immunology Research.* 2022 May 23;2022.
  46. Jin, L., Sun, S., Ryu, Y. et al. Gallic acid improves cardiac dysfunction and fibrosis in pressure overload-induced heart failure. *Sci Rep* 8, 9302 (2018). <https://doi.org/10.1038/s41598-018-27599-4>
  47. Ganeshpurkar A., Saluja A. K. (2017). Protective Effect of Rutin on Humoral and Cell Mediated Immunity in Rat Model. *Chemico-Biological Interactions* 273, 154–159. doi:10.1016/j.cbi.2017.06.006
  48. Simunkova M., Alwasel S. H., Alhazza I. M., Jomova K., Kollar V., Rusko M., et al. (2019). Management of Oxidative Stress and Other Pathologies in Alzheimer's Disease. *Arch. Toxicol.* 93 (9), 2491–2513. doi:10.1007/s00204-019-02538-y
  49. Meng XL, Yu MM, Liu YC, Gao YL, Chen XS, Shou ST, Chai YF. Rutin Inhibits Cardiac Apoptosis and Prevents Sepsis-Induced Cardiomyopathy. *Front Physiol.* 2022 Apr 14;13:834077. doi: 10.3389/fphys.2022.834077. PMID: 35492613; PMCID: PMC9050354.
  50. Siti HN, Jalil J, Asmadi AY, Kamisah Y. Roles of rutin in cardiac remodeling. *Journal of Functional Foods.* 2020 Jan 1;64:103606.
  51. Joshi, B.R., Hakim, M.M. & Patel, I.C. The biological active compounds and biological activities of *Desmodium* species from Indian region: a review. *Beni-Suef Univ J Basic Appl Sci* 12, 1 (2023). <https://doi.org/10.1186/s43088-022-00339-4>
  52. Gormaz Guillermo Juan, Quintremil Sebastian and Rodrigo Ramon, Cardiovascular Disease: A Target for the Pharmacological Effects of Quercetin, *Current Topics in Medicinal Chemistry* 2015; 15(17). <https://dx.doi.org/10.2174/1568026615666150427124357>
  53. Meena AK, Motiwale M, Ilavarasan R, Perumal A, Singh R, Srikanth N, Dhiman KS. Evaluation of Substitution of Small Branches with Roots of *Desmodium gangeticum* (Physicochemical Analysis, HPLC, and GC-MS Profiling) and In Silico Study of Pterocarpanes for Pharmacological Target. *Appl Biochem Biotechnol.* 2022 Apr;194(4):1527-1545. doi: 10.1007/s12010-021-03696-5. Epub 2021 Nov 18. PMID: 34792750.
  54. Abdelsalam, Korashy, Zeidan, Agouni. The Role of Protein Tyrosine Phosphatase (PTP)-1B in Cardiovascular Disease and Its Interplay with Insulin Resistance. *Biomolecules* [Internet] 2019;9(7):286. Available from: <http://dx.doi.org/10.3390/biom9070286>
  55. Ghosh D, Anandakumar A. Anti-inflammatory and analgesic activities of gangetin—a pterocarpenoid from *Desmodium gangeticum*. *Indian Journal of Pharmacology.* 1983 Oct 1;15 (4):391.
  56. Atiya A, Batra S, Mohammad T, Alorfi NM, Abdulmonem WA, Alhumaydhi FA, Ashraf GM, Baeesa SS, Elsbali AM, Shahwan M. Desmodin and isopongachromene as potential inhibitors of cyclin-dependent kinase 5: phytoconstituents targeting anticancer and neurological therapy. *Journal of Biomolecular Structure and Dynamics.* 2022 Sep 27:1-1.
  57. Leitch AE, Haslett C, Rossi AG. Cyclin-dependent kinase inhibitor drugs as potential novel anti-inflammatory and pro-resolution agents. *Br J Pharmacol.* 2009 Oct;158(4):1004-16. doi: 10.1111/j.1476-5381.2009.00402.x. Epub 2009 Sep 23. PMID: 19775281; PMCID: PMC2785523.
  58. National Center for Biotechnology Information. PubChem Compound Summary for CID 10095180, kaempferol 7-O-glucoside. <https://pubchem.ncbi.nlm.nih.gov/compound/10095180>. Accessed Mar. 17, 2023.
  59. Akhilesh K. Yadav , Jyoti Agrawal , Anirban Pal & Madan M. Gupta (2013): Novel anti-inflammatory phytoconstituents from *Desmodium gangeticum* , *Natural Product Research: Formerly Natural Product Letters*, DOI:10.1080/14786419.2012.761620
  60. Akhilesh K. Yadav, Jyoti Agrawal, Anirban Pal & Madan M. Gupta (2013): Novel anti-inflammatory phytoconstituents from *Desmodium gangeticum*, *Natural Product Research: Formerly Natural Product Letters*, DOI:10.1080/14786419.2012.761620
  61. Cai Y, Xin Q, Lu J, Miao Y, Lin Q, Cong W, Chen K. A new therapeutic candidate for cardiovascular diseases: Berberine. *Frontiers in pharmacology.* 2021 Mar 17; 12:631100.
  62. Xiao B, Huang X, Wang Q, Wu Y. Beta-Asarone Alleviates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammatory Response and NLRP3 Inflammasome Mediated Pyroptosis. *Biological and Pharmaceutical Bulletin.* 2020 Jul 1;43(7):1046-51.
  63. Hapke HJ, Strathmann W. Pharmakologische Wirkungen des Hordenin [Pharmacological effects of hordenine]. *Dtsch*

- Tierarztl Wochenschr. 1995 Jun;102(6):228-32. German. PMID: 8582256.
64. Ghisalberti EL, Pennacchio M, Alexander E. Survey of secondary plant metabolites with cardiovascular activity. *Pharmaceutical biology*. 1998 Jan 1;36(4):237-79.
  65. Xia LM, Luo MH. Study progress of berberine for treating cardiovascular disease. *Chronic Dis Transl Med*. 2016 Jan 12;1(4):231-235. doi: 10.1016/j.cdtm.2015.11.006. PMID: 29063012; PMCID: PMC5643735.
  66. Wang H, Shi H, Lu Y, Yang B, Wang Z. Pilocarpine modulates the cellular electrical properties of mammalian hearts by activating a cardiac M3 receptor and a K<sup>+</sup> current. *Br J Pharmacol*. 1999 Apr;126(8):1725-34. doi: 10.1038/sj.bjpp.0702486. PMID: 10372814; PMCID: PMC1565960.
  67. Consolim-Colombo FM, Sangaleti CT, Costa FO, Morais TL, Lopes HF, Motta JM, Irigoyen MC, Bortoloto LA, Rochitte CE, Harris YT, Satapathy SK. Galantamine alleviates inflammation and insulin resistance in patients with metabolic syndrome in a randomized trial. *JCI insight*. 2017 Jul 7;2(14).
  68. Hou X, Fu M, Cheng B, Kang Y, Xie D. Galanthamine improves myocardial ischemia-reperfusion-induced cardiac dysfunction, endoplasmic reticulum stress-related apoptosis, and myocardial fibrosis by suppressing AMPK/Nrf2 pathway in rats. *Ann Transl Med*. 2019 Nov;7(22):634. doi: 10.21037/atm.2019.10.108. PMID: 31930035; PMCID: PMC6944599.
  69. Zhang H, Zhang RH, Liao XM, Yang D, Wang YC, Zhao YL, Xu GB, Liu CH, Li YJ, Liao SG, Zhou M. Discovery of  $\beta$ -carboline derivatives as a highly potent cardioprotectant against myocardial ischemia-reperfusion injury. *Journal of Medicinal Chemistry*. 2021 Jun 16;64(13):9166-81.
  70. Khurana S, Venkataraman K, Hollingsworth A, Piche M, Tai TC. Polyphenols: benefits to the cardiovascular system in health and in aging. *Nutrients*. 2013 Sep 26;5(10):3779-827. doi: 10.3390/nu5103779. PMID: 24077237; PMCID: PMC3820045.
  71. Bondonno NP, Bondonno CP, Rich L, Mas E, Shinde S, Ward NC, Hodgson JM, Croft KD. Acute effects of quercetin-3-O-glucoside on endothelial function and blood pressure: a randomized dose-response study. *Am J Clin Nutr*. 2016 Jul;104(1):97-103. doi: 10.3945/ajcn.116.131268. Epub 2016 May 11. PMID: 27169837.
  72. Kabera JN, Semana E, Mussa AR, He X. Plant secondary metabolites: biosynthesis, classification, function and pharmacological properties. *J. Pharm. Pharmacol*. 2014 Jan;2(7):377-92.
  73. Vagbhata. *Ashtanga Hridayam with bhashavyakhyana of Cheppatt K Achyuta Warriar*. 10 reprint ed. Kodungalloor: Devi book stall; 2005. Uttarasthana-Part 2, Chapter 24. Sirorogapratishedam, Sloka 10; p.81.
  74. Jiménez-González L, Hernández-Cervantes C, Álvarez-Corral M, Muñoz-Dorado M, Rodríguez-García I. Synthesis of Pterocarpan. *Natural Product Communications*. 2011;6(4). doi:10.1177/1934578X1100600414
  75. Selvam C, Jordan BC, Prakash S, Mutisya D, Thilagavathi R. Pterocarpan scaffold: A natural lead molecule with diverse pharmacological properties. *Eur J Med Chem*. 2017 Mar 10;128:219-236. doi: 10.1016/j.ejmech.2017.01.023. Epub 2017 Jan 17. PMID: 28189086.
  76. Plat J, Baumgartner S, Vanmierlo T, Lütjohann D, Calkins KL, Burrin DG, Guthrie G, Thijs C, Te Velde AA, Vreugdenhil ACE, Sverdlow R, Garssen J, Wouters K, Trautwein EA, Wolfs TG, van Gorp C, Mulder MT, Riksen NP, Groen AK, Mensink RP. Plant-based sterols and stanols in health & disease: "Consequences of human development in a plant-based environment?". *Prog Lipid Res*. 2019 Apr;74:87-102. doi: 10.1016/j.plipres.2019.02.003. Epub 2019 Feb 26. PMID: 30822462.
  77. Dutta A, Dutta SK. Vitamin E and its role in the prevention of atherosclerosis and carcinogenesis: a review. *J Am Coll Nutr*. 2003 Aug;22(4):258-68. doi: 10.1080/07315724.2003.10719302. PMID: 12897039.
  78. Salehi B, Quispe C, Sharifi-Rad J, Cruz-Martins N, Nigam M, Mishra AP, Kononov DA, Orobinskaya V, Abu-Reidah IM, Zam W, Sharopov F, Venneri T, Capasso R, Kukula-Koch W, Wawruszak A, Koch W. Phytosterols: From Preclinical Evidence to Potential Clinical Applications. *Front Pharmacol*. 2021 Jan 14;11:599959. doi: 10.3389/fphar.2020.599959. PMID: 33519459; PMCID: PMC7841260.
  79. Meena, A.K., Motiwale, M., Ilavarasan, R. et al. Evaluation of Substitution of Small Branches with Roots of *Desmodium gangeticum* (Physicochemical Analysis, HPLC, and GC-MS Profiling) and In Silico Study of Pterocarpan for Pharmacological Target. *Appl Biochem Biotechnol* 194, 1527–1545 (2022). <https://doi.org/10.1007/s12010-021-03696-5>
  80. Kamaruddin NA, Hakim Abdullah MN, Tan JJ, Lim V, Fong LY, Abd Ghafar SA, Yong YK. Vascular Protective Effect and Its Possible Mechanism of Action on Selected Active Phytocompounds: A Review. *Evid Based Complement Alternat Med*. 2022 Apr 16; 2022:3311228. doi: 10.1155/2022/3311228. PMID: 35469164; PMCID: PMC9034927.
  81. Steven S, Frenis K, Oelze M, Kalinovic S, Kuntic M, Bayo Jimenez MT, Vujacic-Mirski K, Helmstädter J, Kröller-Schön S, Münzel T, Daiber A. Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease. *Oxid Med Cell Longev*. 2019 Jun 23;2019:7092151. doi: 10.1155/2019/7092151. PMID: 31341533; PMCID: PMC6612399.

§§§